Synthesis and evaluation of two technetium-99m-labeled peptidic 2-nitroimidazoles for imaging hypoxia
CA 2266298 A1 · Owner: Ballinger, James R. · Inventors: Thornback, John R.; Zhang, Xiuguo; Pollak, Alfred
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The presence of hypoxic cells in solid tumors is a marker for therapy resistant, aggressive disease. The non-invasive detection of hypoxic cells in tumors by radiolabeled 2-nitroimidazoles is a diagnostic technique under current evaluation. Two, peptidic chelating agents dimethylglycyl-L-seryl-L-cysteinyl-lysyl{N E-1-(2nitro-1H-, imidazolyl)acetamido}-glycine (RP435) and dimethylglycyl-tert-butylglycyl-Lcysteinylglycine-2-(2-nitro-1H-imidazolyl)ethylamide (RP535) have been synthesized. Both chelating agents contain an N3S class chelator for 99m Tc and Re and a , 2-nitroimidazole group which can be enzymatically reduced and trapped in cells under, hypoxic conditions. Two isomers of 99m …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed March 19, 1999. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended March 19, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by March 19, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.